XORTX Therapeutics Inc.
XRTXHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeXORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. At a $1.7M market cap, XORTX Therapeutics Inc. ranks as a micro-cap company within healthcare. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
Market Cap
$1.7M
Beta
0.58
P/E (TTM)
—
P/E (Fwd)
1.15
EPS (TTM)
$-2.61
EPS (Fwd)
$0.80
ROE
-99.2%
ROA
-29.8%
Cash
$994,045
Total Debt
$0
Free CF
-$2.6M
52W Change
-72.3%
Annual Financials
Cash vs Debt
Where XRTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, XRTX finished 53.02% below its 150-day moving average ($2.15) and 54.30% below its 200-day moving average ($2.21). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XRTX overbought or oversold?
At the October 20, 2026 close, XRTX's RSI(14) was 29.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
XORTX Therapeutics Inc. reports $994K in cash and $0 in total debt. Free cash flow is running at -$2.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -99.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.58 suggests XRTX is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing XRTX.